20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Binding of Dopamine to Bovine Anterior Pituitary Gland Membranes

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          [<sup>3</sup>H]-dopamine (DA) binding to bovine anterior pituitary membranes was measured using sensitive in vitro ultrafiltration and centrifugation techniques. The specific interaction of [<sup>3</sup>H]-DA with the membrane fraction reached a steady-state level within 15 min at 30°C and was reversible by incubating with excess nonradioactive DA. Scatchard analysis suggests the presence of 2 sites for DA specific binding having K < j values of 4.4 × 10<sup>–10</sup> M and 4.7 × 10<sup>–8</sup> M, respectively. Correspondingly, the total receptor concentrations were calculated to be 336 and 2,340 pmoles/g protein. Blockade of [<sup>3</sup>H]-DA binding was produced most effectively by ergocryptine and apomorphine. Perphenazine and haloperidol were considerably less active and pimozide did not compete. The importance of DA in the regulation of prolactin (Prl) secretion and the characterization of pituitary DA receptor sites are discussed.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1978
          1978
          25 March 2008
          : 25
          : 1
          : 32-46
          Affiliations
          Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia School of Medicine Charlottesville, Va.
          Article
          122762 Neuroendocrinology 1978;25:32–46
          10.1159/000122762
          652118
          34c979ed-9139-4def-b39c-0a7be83fb1f9
          © 1978 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 06 May 1977
          : 09 August 1977
          Page count
          Pages: 15
          Categories
          Original Paper

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Perphenazine,Dopamine agonists,Dopamine receptors,Dopamine antagonists,Ergocryptine,Pituitary gland,Haloperidol,Apomorphine,Prolactin secretion

          Comments

          Comment on this article